zinc sulfate supplementation in Glioblastoma multiform

Effect of zinc sulfate supplementation on overall and progression free survival in patients receiving adjuvant chemoradiation for Glioblastoma multiform

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190430043432N1

Enrollment

Registered

2019-12-01

Start date

2019-12-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma multiform. Malignant neoplasm of brain

Interventions

Intervention group: Intake of 100 mg zinc sulfate supplement capsule daily from the beginning of chemoradiation adjuvant therapy for 30 weeks..

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: New diagnosed patients with glioblastoma multi form Normal function of liver, kidneys and hematologic system Normal zinc and cupper serum levels

Exclusion criteria

Exclusion criteria: Pregnancy History of another malignancy History of allergy to zinc sulfate supplementation

Design outcomes

Primary

Measure	Time frame
Lifetime from diagnosis to death. Timepoint: Every 3 months to at least 12 months. Method of measurement: Visit the patients and find out if they are alive (Survival Calculation by Week).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Kameli

Shiraz University of Medical Sciences

parisa.kameli@ymail.com+98 71 3626 8538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026